Sugi Predict

Sugi Predict / Targets / MAPK6

MAPK6

Mitogen-activated protein kinase 6 · Q16659 · MAPK6 on Sugi Atlas →

11,716 patent compounds predicted against MAPK6, 7,668 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1663652 SCHEMBL1663652 0.62 5/20
SCHEMBL1663793 SCHEMBL1663793 0.59 5/20
SCHEMBL1574004 SCHEMBL1574004 0.59 5/20
SCHEMBL1145076 SCHEMBL1145076 0.57 5/20
SCHEMBL12222 SCHEMBL12222 0.56 5/20
SCHEMBL1922328 SCHEMBL1922328 0.55 5/20
SCHEMBL695280 SCHEMBL695280 0.42 5/20
SCHEMBL1663211 SCHEMBL1663211 0.51 4/20
SCHEMBL1144846 SCHEMBL1144846 0.50 4/20
SCHEMBL1144879 SCHEMBL1144879 0.50 4/20
SCHEMBL1145032 SCHEMBL1145032 0.50 4/20
SCHEMBL473508 SCHEMBL473508 0.47 4/20
SCHEMBL473509 SCHEMBL473509 0.47 4/20
SCHEMBL473439 SCHEMBL473439 0.47 4/20
SCHEMBL473440 SCHEMBL473440 0.47 4/20
SCHEMBL599945 SCHEMBL599945 0.42 4/20
SCHEMBL1513065 SCHEMBL1513065 0.70 3/20
SCHEMBL1406065 SCHEMBL1406065 0.61 3/20
SCHEMBL1513026 SCHEMBL1513026 0.59 3/20
SCHEMBL699588 SCHEMBL699588 0.54 3/20

Clinical trials — most relevant to MAPK6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility. PHASE3UNKNOWN
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen PHASE2COMPLETED
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... PHASE2COMPLETED
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery PHASE2WITHDRAWN
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC PHASE2NOT_YET_RECRUITING
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma PHASE2COMPLETED
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer PHASE2COMPLETED
GW572016 to Treat Recurrent Malignant Brain Tumors PHASE2COMPLETED
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies PHASE1RECRUITING
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage nanCOMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC) nanRECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Histiocytic Disorder Follow-up Study nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a MAPK6 binder may also engage these)

ProteinNameSimilarity
Q5R7U1 — 0.998 Q5R7U1 →
Q61532 — 0.997 Q61532 →
Q5F3W3 — 0.996 Q5F3W3 →
P27704 — 0.995 P27704 →
B2GUY1 — 0.988 B2GUY1 →
O70551 — 0.987 O70551 →
Q9CAV6 — 0.987 Q9CAV6 →
Q8C0P0 — 0.986 Q8C0P0 →
P46200 — 0.986 P46200 →
Q6NTJ3 — 0.986 Q6NTJ3 →
CDC7 Cell division cycle 7-related protein kinase 0.986 landscape →
P32581 — 0.985 P32581 →
Q9LFA2 — 0.985 Q9LFA2 →
A6ZZF6 — 0.985 A6ZZF6 →
Q61IS6 — 0.985 Q61IS6 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.985 landscape →
F4ICB6 — 0.985 F4ICB6 →
Q8WML3 — 0.984 Q8WML3 →
Q03563 — 0.984 Q03563 →
O13889 — 0.984 O13889 →
A7MBB4 — 0.984 A7MBB4 →
Q9Z2R9 — 0.984 Q9Z2R9 →
Q0WPH8 — 0.984 Q0WPH8 →
A6QP06 — 0.984 A6QP06 →
Q8TFG6 — 0.984 Q8TFG6 →
Q62661 — 0.984 Q62661 →
D2HXI8 — 0.984 D2HXI8 →
Q9TTK0 — 0.983 Q9TTK0 →
Q5R8X7 — 0.983 Q5R8X7 →
Q2PFD7 — 0.983 Q2PFD7 →